Is pharma investing in the right digital solutions?

Digital transformation has gathered pace in pharma and we have all been witnessing the acceleration. New technologies have been adopted to ensure HCP engagement is maintained but keeping up the understanding of innovative and emerging solutions and investing in the right technologies may prove challenging.

A report authored by Reuters Events Pharma and Elsevier discusses that spending on digital is likely to take a larger proportion of promotional budgets moving forward. It is anticipated that budgets for digital promotion are likely to increase by over 23% in the next three years, while print promotion will drop by 40%.

It is clear that there is an appetite for changing the promotional landscape, but spending the additional digital budget wisely is critical to the return on investment. Tangent90’s Trustrack solution comprehensively manages the distribution of published digital scientific content, aligning well with the ‘science first’ approach adopted by many pharma companies for their HCP digital engagement approach. As one of the first-ever Veeva Silver Certified Technology Partners, we have developed a solution which enables pharma to share digital copyright content direct with HCPs – managing the publishers’ intellectual property at source. The distribution and tracking of peer-reviewed scientific publications, as well as related published digital content such as quick-take videos, help drive meaningful engagement with HCPs and works within pharma’s existing ecosystem and using their existing channels. It provides a complete 360-degree view of what content has been shared and how it has been used, which is fed directly back to pharma’s CRM. This process provides actionable insights, as well as complete control of the volume of content shared to avoid overwhelming the HCP.

To find out more about how Tangent90 can support you to manage your digital scientific content distribution, please contact us at hello@tangent90.com.

Related news

First party data

The first-party data opportunity

The pharma industry has embraced the digital revolution and with that the opportunity to use more readily available data. However, effective digital engagement only works if first-party data (information a company collects directly from its customers and owns) is collected and subsequently used properly.

HCP access

Taking advantage of the HCP access rebound

The latest Veeva Pulse Field Trends Report is out and it discusses the change in access to HCPs. Even pre-pandemic, face-to-face meetings were in decline but the report highlights that this has bounced back, and some. The figure now sits at 60% across all specialities but what is clear is that how interaction takes place has changed.

Marketing insight

Harnessing data-driven HCP engagement

Whether it’s via email, from a congress booth, or a website, we share content with our target audience constantly. For pharma, this content can be the difference between an HCP prescribing their drug or not. It is, therefore, important to understand what happens to that content after the initial interaction with the HCP.

Scroll to Top

Book A Demo

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.